ES2149888T3 - 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias. - Google Patents
3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias.Info
- Publication number
- ES2149888T3 ES2149888T3 ES94929281T ES94929281T ES2149888T3 ES 2149888 T3 ES2149888 T3 ES 2149888T3 ES 94929281 T ES94929281 T ES 94929281T ES 94929281 T ES94929281 T ES 94929281T ES 2149888 T3 ES2149888 T3 ES 2149888T3
- Authority
- ES
- Spain
- Prior art keywords
- phosphodiesterase
- type
- inflammatory diseases
- pirrolidinas
- dioxifenil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
SE PRESENTAN NUEVOS COMPUESTOS DE PIRROLIDINA DE LA FORMULA (I) QUE SON UTILES PARA INHIBIR LA FUNCION DE LA FOSFODIESTERASA TIPO IV (PDE-IV) ASI COMO METODOS PARA LA PRODUCCION DE LOS MISMOS. TAMBIEN SE PRESENTAN APLICACIONES PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y DE OTRAS ENFERMEDADES EN LAS QUE INTERVIENEN NIVELES ELEVADOS DE CITOQUINAS, ASI COMO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL (SNC).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/123,837 US5665754A (en) | 1993-09-20 | 1993-09-20 | Substituted pyrrolidines |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2149888T3 true ES2149888T3 (es) | 2000-11-16 |
Family
ID=22411191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES94929281T Expired - Lifetime ES2149888T3 (es) | 1993-09-20 | 1994-09-20 | 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias. |
Country Status (11)
Country | Link |
---|---|
US (1) | US5665754A (es) |
EP (1) | EP0720600B1 (es) |
JP (2) | JP3847333B2 (es) |
AT (1) | ATE194593T1 (es) |
AU (1) | AU685170B2 (es) |
CA (1) | CA2171448A1 (es) |
DE (1) | DE69425267T2 (es) |
ES (1) | ES2149888T3 (es) |
HK (1) | HK1011972A1 (es) |
NZ (1) | NZ274381A (es) |
WO (1) | WO1995008534A1 (es) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665754A (en) * | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
US6514949B1 (en) | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
US6448235B1 (en) | 1994-07-11 | 2002-09-10 | University Of Virginia Patent Foundation | Method for treating restenosis with A2A adenosine receptor agonists |
US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
US6372770B1 (en) | 1994-10-12 | 2002-04-16 | Euro-Celtique, S.A. | Benzoxazoles |
DE69630214T2 (de) | 1995-03-10 | 2004-07-15 | Berlex Laboratories, Inc., Richmond | Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien |
US5612353A (en) * | 1995-06-07 | 1997-03-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
JP4017214B2 (ja) | 1996-06-11 | 2007-12-05 | 興和創薬株式会社 | 5−フェニル−3−ピリダジノン誘導体 |
JP4373497B2 (ja) | 1996-06-19 | 2009-11-25 | ローン−プーラン・ロレ・リミテツド | 置換されたアザビシクロ化合物、ならびにtnfおよびサイクリックampホスホジエステラーゼ産生の阻害剤としてのそれらの使用 |
CA2262502C (en) | 1996-07-31 | 2002-11-26 | Nikken Chemicals Co., Ltd. | 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same |
US6265402B1 (en) | 1996-08-27 | 2001-07-24 | Nikken Chemicals Co., Ltd. | Use of 2-phenylmorpholin-5-one derivatives |
US5922557A (en) * | 1997-01-09 | 1999-07-13 | Merck & Co., Inc. | System for stably expressing a high-affinity camp phosphodiesterase and use thereof |
WO1998058901A1 (fr) | 1997-06-24 | 1998-12-30 | Nikken Chemicals Co., Ltd. | Derives de la 3-anilino-2-cycloalcenone |
US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
JP4518587B2 (ja) * | 1998-03-09 | 2010-08-04 | 興和創薬株式会社 | 2−フェニルモルホリン誘導体 |
US20030232777A1 (en) * | 2002-06-18 | 2003-12-18 | Marcusson Eric G. | Phosphatidylinositol-4-phosphate 5-kinase, type II beta inhibitors for inhibiting angiogenesis |
US20030232775A1 (en) * | 2002-06-18 | 2003-12-18 | Isis Pharmaceuticals Inc. | Antisense modulation of phosphatidylinositol-4-phosphate 5-kinase, type II beta expression |
US6399649B1 (en) * | 1998-09-24 | 2002-06-04 | Boston Medical Center Corporation | Compositions and methods for the treatment of chronic lymphocytic leukemia |
US7427606B2 (en) * | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
US7378400B2 (en) * | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
US6232297B1 (en) * | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
PT1212089E (pt) | 1999-08-21 | 2006-08-31 | Altana Pharma Ag | Combinacao sinergica de roflumilast e salmeterol |
US6680336B2 (en) * | 1999-12-15 | 2004-01-20 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
US6376489B1 (en) * | 1999-12-23 | 2002-04-23 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
US6258833B1 (en) * | 1999-12-23 | 2001-07-10 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
US6348602B1 (en) * | 1999-12-23 | 2002-02-19 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
US6362213B1 (en) | 1999-12-23 | 2002-03-26 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
US6294561B1 (en) | 1999-12-23 | 2001-09-25 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
US6372777B1 (en) * | 1999-12-23 | 2002-04-16 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
US6313156B1 (en) | 1999-12-23 | 2001-11-06 | Icos Corporation | Thiazole compounds as cyclic-AMP-specific phosphodiesterase inhibitors |
US6569885B1 (en) | 1999-12-23 | 2003-05-27 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
US6900232B2 (en) | 2000-06-15 | 2005-05-31 | Pharmacia Corporation | Cycloalkyl alkanoic acids as integrin receptor antagonists |
IT1317049B1 (it) | 2000-06-23 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Composti utili per la preparazione di medicamenti ad attivita'inibitrice della fosfodiesterasi iv. |
US6670334B2 (en) | 2001-01-05 | 2003-12-30 | University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
WO2002094321A1 (fr) * | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | Compositions favorisant la guérison d'une fracture osseuse |
EP1389467B1 (en) * | 2001-05-23 | 2013-07-03 | Mitsubishi Tanabe Pharma Corporation | Therapeutic composition for the regenerative treatment of cartilage diseases |
US20040043988A1 (en) * | 2001-06-15 | 2004-03-04 | Khanna Ish Kurmar | Cycloalkyl alkanoic acids as intergrin receptor antagonists |
WO2003029264A2 (en) * | 2001-10-01 | 2003-04-10 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
KR20090080573A (ko) * | 2001-10-16 | 2009-07-24 | 메모리 파마슈티칼스 코포레이션 | 신경계 증후군의 치료를 위한 pde-4 억제제로서의 4-(4-알콕시-3-히드록시페닐)-2-피롤리돈 유도체 |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
AU2003262187A1 (en) * | 2002-04-12 | 2003-10-27 | Celgene Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
KR20050115331A (ko) | 2003-04-01 | 2005-12-07 | 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. | 불임증 포스포디에스터라제의 억제제 |
JPWO2005068427A1 (ja) * | 2004-01-14 | 2007-09-06 | 武田薬品工業株式会社 | カルボキサミド誘導体およびその用途 |
US20060025468A1 (en) * | 2004-07-29 | 2006-02-02 | Whitten Jeffrey P | Chiral pyrrolidine derivatives, and methods for preparing compounds thereof |
WO2006023272A1 (en) * | 2004-08-02 | 2006-03-02 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having a2a agonist activity |
WO2006028618A1 (en) * | 2004-08-02 | 2006-03-16 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
NZ553288A (en) * | 2004-08-02 | 2010-12-24 | Univ Virginia | 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity |
US20070270471A1 (en) * | 2004-08-09 | 2007-11-22 | Glaxo Group Limited | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine |
US20080051379A1 (en) * | 2004-12-01 | 2008-02-28 | Trustees Of Boston University | Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms |
WO2007025177A2 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
WO2007092936A2 (en) * | 2006-02-08 | 2007-08-16 | University Of Virginia Patent Foundation | Method to treat gastric lesions |
WO2007120972A2 (en) | 2006-02-10 | 2007-10-25 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2026813A2 (en) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | アンジオテンシン調節による神経新生 |
US8188063B2 (en) * | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
BRPI0716604A2 (pt) | 2006-09-08 | 2013-04-09 | Braincells Inc | combinaÇÕes contendo um derivado de 4-acilaminopiridina |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
CN101772513B (zh) | 2007-06-04 | 2013-11-13 | 协同医药品公司 | 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂 |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CN101808987A (zh) * | 2007-06-05 | 2010-08-18 | Nsab神经研究瑞典公司分公司 | 作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷 |
US8058259B2 (en) * | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
EP2328910B1 (en) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
AU2010247141A1 (en) | 2009-05-15 | 2011-12-15 | Redx Pharma Plc | Redox drug derivatives |
GB201000499D0 (en) * | 2010-01-13 | 2010-03-03 | Fleet George W J | Treatment of cystic fibrosis |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
WO2012118972A2 (en) | 2011-03-01 | 2012-09-07 | Synegy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
JP6499591B2 (ja) | 2013-02-25 | 2019-04-10 | シナジー ファーマシューティカルズ インコーポレイテッド | 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト |
JO3264B1 (ar) * | 2013-03-13 | 2018-09-16 | Lilly Co Eli | مركبات ازيتيدينيل أوكسي فينيل بيروليدين |
JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
CA2913737A1 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
KR102456567B1 (ko) | 2013-08-09 | 2022-10-19 | 알데릭스, 인코포레이티드 | 인산염 수송을 억제하기 위한 화합물 및 방법 |
GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
CA2976741C (en) | 2015-03-30 | 2023-01-17 | Mission Therapeutics Limited | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
GB201521109D0 (en) * | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
WO2017163078A1 (en) | 2016-03-24 | 2017-09-28 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
RU2711991C1 (ru) * | 2016-07-12 | 2020-01-23 | Гуандун Рейновент Биотек Ко., Лтд. | Производные пирролидина в качестве агонистов ppar |
GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
WO2018089406A1 (en) * | 2016-11-10 | 2018-05-17 | Bristol-Myers Squibb Company | Ror gamma modulators |
WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
CN113563246A (zh) * | 2020-04-29 | 2021-10-29 | 广东东阳光药业有限公司 | 取代的氮杂五元环类衍生物及其在药物中的应用 |
WO2022192340A1 (en) * | 2021-03-10 | 2022-09-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule allosteric modulators of class b gpcr, the pthr, and method to identify them |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3635982A (en) * | 1969-04-08 | 1972-01-18 | American Home Prod | Amino-substituted-quinoxalinyloxazolidines and -oxazines |
US3644398A (en) * | 1969-04-11 | 1972-02-22 | Robins Co Inc A H | 1-carbamoyl-3-phenylpyrrolidines |
JPS4916872B1 (es) * | 1970-05-12 | 1974-04-25 | ||
GB1350582A (en) * | 1970-07-24 | 1974-04-18 | Ucb Sa | Cerivatives of 2-pyrrolidinone |
BE804701A (en) * | 1972-09-11 | 1974-03-11 | Sandoz Sa | 3-Substd phenyl-3-substd alkyl-butyrophenone derivs - useful as anal-gesics, prepd eg by oxidn of corresp alcohols |
DE2413935A1 (de) * | 1974-03-20 | 1975-10-16 | Schering Ag | 4-(polyalkoxy-phenyl)-2-pyrrolidone |
JPS5182258A (ja) * | 1974-04-25 | 1976-07-19 | Yoshitomi Pharmaceutical | Pirorijinonjudotaino seizoho |
DE2541855A1 (de) * | 1975-09-18 | 1977-03-31 | Schering Ag | 4-(polyalkoxy-phenyl)-2-pyrrolidone ii |
JPS52156859A (en) * | 1976-06-18 | 1977-12-27 | Yoshitomi Pharmaceut Ind Ltd | Heterocyclic amide derivatives |
GB1561411A (en) * | 1977-02-25 | 1980-02-20 | Science Union & Cie | 2-phenoxyphenyl pyrrolidines and pharmaceutical compositions containing them |
GB1593888A (en) * | 1977-12-22 | 1981-07-22 | Wyeth John & Brother Ltd | Hexahydroazepine piperidine and pyrrolidine derivatives |
US4219560A (en) * | 1978-04-17 | 1980-08-26 | Sandoz, Inc. | Piperidine and pyrrolidine alcohols |
JPS584711B2 (ja) * | 1978-08-02 | 1983-01-27 | 参天製薬株式会社 | ピロリジン誘導体 |
IE49912B1 (en) * | 1979-07-03 | 1986-01-08 | Wyeth John & Brother Ltd | Hexanhydrozxepine,piperidine and pyrrolidine derivatives |
DE3104435A1 (de) * | 1981-02-03 | 1982-11-11 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Wirkstoffkombination |
US4584313A (en) * | 1984-05-07 | 1986-04-22 | Warner-Lambert Company | (Substituted-phenyl)-5-oxo-2-pyrrolidinepropanoic acids and esters thereof, and use for reversing electroconvulsive shock-induced amnesia |
SU1298204A1 (ru) * | 1985-11-21 | 1987-03-23 | МГУ им.М.В.Ломоносова | Способ получени 3,4-диарил-гамма-аминомасл ных кислот или их циклических амидов |
HU215433B (hu) * | 1986-04-29 | 2000-05-28 | Pfizer Inc. | Eljárás új 2-oxo-5-fenil-pirimidin-származékok előállítására |
DE3732930A1 (de) * | 1987-09-30 | 1989-04-20 | Basf Ag | Fungizide n-substituierte 3-aryl-pyrrolidin-derivate |
DE3732910A1 (de) * | 1987-09-30 | 1989-04-20 | Basf Ag | Fungizide n-substituierte 3-alkyl-4-aryl-pyrrolidin-derivate |
US4960457A (en) * | 1988-12-27 | 1990-10-02 | Ici Americas Inc. | Substituted 1,3-diphenyl pyrrolidones and their use as herbicides |
US5444083A (en) * | 1989-02-03 | 1995-08-22 | Eisai Co., Ltd. | Pyrrolidine compound and pharmaceutical use |
DD299058A5 (de) * | 1990-01-31 | 1992-03-26 | Arzneimittelwerk Dresden Gmbh,De | Verfahren zur herstellung von n-acyl-4-phenyl-pyrrolidin-2-onen mit cerebroprotektiver wirkung |
GB9009395D0 (en) * | 1990-04-26 | 1990-06-20 | Orion Yhtymae Oy | Cyclic hydroxamic acids and their use |
ZW9091A1 (en) * | 1990-07-10 | 1992-04-29 | Smithkline Beecham Corp | Oxamides |
WO1992002220A1 (en) * | 1990-08-03 | 1992-02-20 | Smithkline Beecham Corporation | Tnf inhibitors |
US5124455A (en) * | 1990-08-08 | 1992-06-23 | American Home Products Corporation | Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents |
AU9030691A (en) * | 1990-11-06 | 1992-05-26 | Smithkline Beecham Corporation | Imidazolidinone compounds |
IE71647B1 (en) * | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
US5270328A (en) * | 1991-03-29 | 1993-12-14 | Eli Lilly And Company | Peripherally selective piperidine opioid antagonists |
US5191084A (en) * | 1991-05-01 | 1993-03-02 | American Home Products Corporation | Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents |
PT100441A (pt) * | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
AU2807192A (en) * | 1991-10-02 | 1993-05-03 | Smithkline Beecham Corporation | Cyclopentane and cyclopentene derivatives with antiallergic antiinflammatory and tumor necrosis factor inhibiting activity |
PT100938B (pt) * | 1991-10-09 | 1999-10-29 | Syntex Inc | Compostos benzo e pirido piridazinona e piridazintiona, composicoes farmaceuticas que os contem, utilizacao dos referidos compostos e processo para a sua preparacao. |
WO1993007141A1 (en) * | 1991-10-11 | 1993-04-15 | Smithkline Beecham Corporation | Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production |
US5665754A (en) * | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
-
1993
- 1993-09-20 US US08/123,837 patent/US5665754A/en not_active Expired - Fee Related
-
1994
- 1994-09-20 WO PCT/US1994/010678 patent/WO1995008534A1/en active IP Right Grant
- 1994-09-20 JP JP50990795A patent/JP3847333B2/ja not_active Expired - Fee Related
- 1994-09-20 CA CA002171448A patent/CA2171448A1/en not_active Abandoned
- 1994-09-20 ES ES94929281T patent/ES2149888T3/es not_active Expired - Lifetime
- 1994-09-20 AT AT94929281T patent/ATE194593T1/de active
- 1994-09-20 AU AU78396/94A patent/AU685170B2/en not_active Ceased
- 1994-09-20 EP EP94929281A patent/EP0720600B1/en not_active Expired - Lifetime
- 1994-09-20 DE DE69425267T patent/DE69425267T2/de not_active Expired - Fee Related
- 1994-09-20 NZ NZ274381A patent/NZ274381A/en not_active IP Right Cessation
-
1998
- 1998-12-10 HK HK98113069A patent/HK1011972A1/xx not_active IP Right Cessation
-
2006
- 2006-05-29 JP JP2006148897A patent/JP2006225404A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU7839694A (en) | 1995-04-10 |
US5665754A (en) | 1997-09-09 |
JPH09502979A (ja) | 1997-03-25 |
CA2171448A1 (en) | 1995-03-30 |
NZ274381A (en) | 1998-02-26 |
JP2006225404A (ja) | 2006-08-31 |
HK1011972A1 (en) | 1999-07-23 |
EP0720600B1 (en) | 2000-07-12 |
DE69425267T2 (de) | 2001-01-18 |
DE69425267D1 (de) | 2000-08-17 |
JP3847333B2 (ja) | 2006-11-22 |
AU685170B2 (en) | 1998-01-15 |
WO1995008534A1 (en) | 1995-03-30 |
ATE194593T1 (de) | 2000-07-15 |
EP0720600A1 (en) | 1996-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2149888T3 (es) | 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias. | |
GR3029853T3 (en) | Diazabicyclic neurokinin antagonists | |
HU9303515D0 (en) | Pyrrolo-pyrimidines | |
PT901374E (pt) | Tetra-hidropteridinas e piridilpiperazinas para o tratamento de disturbios neurologicos | |
GB9323165D0 (en) | Compounds | |
RU95113454A (ru) | Катехольные диэфиры как селективные ингибиторы фдэiv, фармацевтическая композиция, способы лечения | |
BG101110A (en) | Substituted pyrimidine compounds and their application | |
DE60027769D1 (de) | Pyrrolidin-derivate als inhibitoren von cyclischer amp-phosphodiesterase | |
BR9305907A (pt) | Uso de derivados de substituída para tratamento de esclerose múltipla | |
PL342078A1 (en) | Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas | |
ATE258175T1 (de) | 3-thiazol-4-yl-pyrrolidinderivate als amp- spezifische phosphodiesterase-inhibitoren | |
DE69703617D1 (de) | Verwendung von optisch reines (+) norcisapride zur behandlung von erbrechen und zns-störungen | |
DK0556332T3 (da) | Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet | |
DE60018470D1 (de) | Cyclische amp spezifische phosphodiesterase inhibitoren | |
NO991734L (no) | Pyrazolinoner for behandling av potensforstyrrelser | |
ATE113591T1 (de) | 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva. | |
PT1017377E (pt) | Utilizacao de 2-aminotetralinas 6,7-substituidas para o tratamento de condicoes inflamatorias mediadas por citoquina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 720600 Country of ref document: ES |